Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reflect a positive sentiment. The company reported strong financial performance, including high single-digit growth in key areas and margin expansion. The guidance was conservative yet confident, with raised EPS expectations and strategic share buybacks. Despite some uncertainties, the overall outlook is optimistic, with a focus on innovation and commercial excellence. The market strategy and shareholder return plans are likely to be well-received, leading to a positive stock price movement.
Key Financial Performance
Q4 Revenue $5.9 billion, increased 7% and 3.9% organic. New BD delivered strong organic growth of 4.9%, accelerating 90 basis points sequentially.
Full Year Revenue $21.8 billion, increased 7.7% and 2.9% organic. New BD grew 3.9% organic.
Adjusted Diluted EPS (Q4) $3.96, representing 9.6% earnings growth including a 2-point impact from tariffs.
Adjusted Diluted EPS (Full Year) $14.40, representing 9.6% earnings growth including a 2-point impact from tariffs.
Shareholder Returns $2.2 billion returned to shareholders, inclusive of a $1 billion share buyback.
Adjusted Gross Margin 54.7% for the full year, up 140 basis points year-over-year.
Adjusted Operating Margin 25% for the full year, up 80 basis points year-over-year.
Free Cash Flow $2.7 billion for fiscal 2025, with a free cash flow conversion of 64%.
Net Leverage 2.8x at the end of fiscal year 2025, progressing towards a target of 2.5x.
Pharm Systems Vaccines Vaccines are approximately 20% of Pharm Systems business. Demand declined rapidly late in Q4, impacting overall performance.
Biosciences Academic and Government Research Research funding remains subdued, but sales in the U.S. and EMEA improved sequentially, led by strong demand for the new FACSDiscover platform.
Diagnostic Solutions Returned to positive growth in Q4 as BD BACTEC utilization continued to recover.
BD Interventional High single-digit growth driven by double-digit growth in PureWick and advanced tissue regeneration.
Advanced Patient Monitoring (APM) Double-digit pro forma growth in the first year of integration, performing well ahead of the deal model.
Pharm Systems Biologics High single-digit growth driven by GLP-1s.
MMS (Medication Management Solutions) Record quarter for Alaris pump installations, including several new competitive wins.
Adjusted Operating Margin Expansion 80 basis points expansion, supported by adjusted gross margin improvement and investments in selling and innovation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FACSDiscover platform: Strong demand in the U.S. and EMEA, contributing to sequential improvement in Biosciences.
BD Incada AI-enabled platform: Recently launched to unify BD device data into one intelligent ecosystem.
BD Pyxis Pro medication dispensing platform: Planned new product launch.
HemoSphere Stream: Received 510(k) clearance for continuous noninvasive blood pressure monitoring module, with commercial launch planned for 2026.
Sales force expansion: Investing $30 million to expand sales force in high-growth markets, including a 15% increase in PI and APM sales forces.
PureWick at home: Capitalizing on recent VA reimbursement and new surgery innovations launching in Europe.
BD Excellence operating model: Drove strong P&L leverage, with adjusted gross margin up 140 basis points and adjusted operating margin expansion of 80 basis points.
Cost optimization program: Initiated a 2-year $200 million cost-out program to address stranded corporate costs.
Free cash flow: Achieved $2.7 billion in fiscal 2025, with a conversion rate of 64%.
Waters transaction: On track to close by the end of Q1 2026, combining Biosciences and Diagnostic Systems with Waters to unlock significant strategic and financial value.
New BD strategy: Focused on creating a pure-play MedTech company with a deep innovation pipeline and a consumables revenue profile of over 90%.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Impact: Greater-than-anticipated impact in macro areas, specifically in Pharm Systems vaccines and Biosciences academic and government research, leading to reduced demand.
Vaccine Demand: Rapidly evolving reductions in vaccine demand, particularly in Q4, impacting approximately 20% of the Pharm Systems business.
Research Funding: Subdued research funding in Biosciences, although some sequential improvement was noted in the U.S. and EMEA.
China Market Dynamics: Mid-teens decline expected in China due to government policies, including volume-based procurement, impacting growth by about 100 basis points.
Tariffs: Incremental $185 million or 80 basis points year-over-year headwind from tariffs, impacting adjusted operating margin.
Alaris Capital Installations: FY '26 is the last year of a 3-year remediation commitment, with expected sales above historical run rates but creating a growth headwind of over 100 basis points.
Regulatory Approvals: Pending regulatory approvals and customary closing conditions for the Waters transaction, which could impact timelines and strategic execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: BD expects low single-digit revenue growth for fiscal 2026, with mid-single-digit growth over the long term. The guidance includes headwinds from reduced Alaris capital installations, mid-teens decline in China due to government policies, and a 25% decline in Pharm Systems Vaccines revenue. Excluding these headwinds, the remaining 90% of the portfolio is expected to grow mid-single digits.
Adjusted Operating Margin: The adjusted operating margin is expected to remain consistent with fiscal 2025 at about 25%, despite an incremental $185 million or 80 basis points year-over-year headwind from tariffs. Margin expansion will primarily come from gross margin improvements driven by BD Excellence.
Adjusted Diluted EPS: Initial adjusted diluted EPS guidance is set at $14.75 to $15.05 for fiscal 2026. Excluding the year-over-year tariff headwind, EPS growth at the midpoint is expected to be high single digits.
Capital Allocation Strategy: BD plans to execute a $250 million share buyback in the first quarter of fiscal 2026 and use at least half of the $4 billion in cash proceeds from the Waters transaction for share repurchases, with the balance for debt repayment.
Innovation and Product Launches: BD is investing nearly $50 million in R&D and businesses to fuel future innovation and growth in high-growth markets. Planned product launches include the BD Incada AI-enabled platform, BD Pyxis Pro medication dispensing platform, and HemoSphere Stream for continuous noninvasive blood pressure monitoring, among others.
Cost Optimization: A 2-year $200 million cost-out program has been initiated to address stranded corporate costs, with approximately half expected to be realized in fiscal 2026.
New BD Strategy: Post the Waters transaction, New BD is expected to deliver similar revenue growth and margin profiles as WholeCo, with pro forma adjusted EPS growth over 200 basis points higher than WholeCo.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increases: BD announced its 54th consecutive year of dividend increases.
Share Buyback: BD returned $2.2 billion to shareholders, inclusive of a $1 billion share buyback.
Future Share Buyback Plans: BD plans to execute another $250 million share buyback this quarter and use at least half of the $4 billion in cash proceeds from the Waters transaction for share repurchases following the closing.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the guidance for New BD reflect conservatism and confidence in delivering on the initial guide, including EPS and margins?
A:Thomas Polen explained that the guidance incorporates a prudent approach to macro dynamics, including updated views on the operating environment, vaccines, Alaris performance, and China. The company has not built any macro environment improvements into the outlook but has confidence in continued margin expansion and EPS performance driven by gross margin expansion from BD Excellence.
Q:What is the confidence level in the Q1 guide versus the full year, and how does the phasing of growth look?
A:Thomas Polen stated that the Q1 guide reflects full-year headwinds, with vaccines having the greatest weighting in Q1. Growth is expected to step up in Q2 and Q3, which will likely be the strongest quarters. The phasing does not rely on back-half ROIC or macro relief, and comps are expected to ease in Q2 and Q3.
Q:Why not be more aggressive in returning capital to shareholders through buybacks, given the stock's yield and valuation?
A:Christopher DelOrefice emphasized a disciplined approach to net leverage ratio and highlighted the Waters transaction as a value creation opportunity. At least half of the $4 billion proceeds from the transaction will go to share buybacks, which will accelerate EPS growth for New BD by over 200 basis points. Thomas Polen added that the intrinsic value of the company is significantly higher than its trading value, justifying the buyback strategy.
Q:What is the expectation for China in fiscal '26, and how does it compare to Q4 and full-year '25?
A:Thomas Polen noted that China was down high single digits organically in Q4. For fiscal '26, the expectation is a mid-teens decline, reflecting a prudent approach to VoBP dynamics. Post-separation, China will represent about 4% of revenue, setting up easier base comparisons in future years.
Q:What are the updated thoughts on the New BD strategy and earnings algorithm?
A:Thomas Polen highlighted the focus on mid-single-digit growth, margin expansion, and at least 50% of free cash flow going to share buybacks. The New BD is positioned as a focused MedTech leader with strong cash generation and a unique value creation strategy in the industry.
Q:How should we think about the Alaris headwind in fiscal '26 and its contribution in fiscal '25?
A:Christopher DelOrefice explained that Alaris contributed significantly in fiscal '25, with the hardest comp in Q1 of fiscal '26. The full-year headwind for fiscal '26 is about 100 basis points, with a normalized run rate expected beyond fiscal '26. Thomas Polen added that the fleet replacement cycle will turn into a tailwind in the 2030s.
Q:How can BD achieve operating margin expansion despite low organic growth?
A:Christopher DelOrefice attributed margin expansion to BD Excellence, which delivered 140 basis points of gross margin improvement in fiscal '25. The strategy includes reinvesting in the business, leveraging G&A, and implementing cost-out programs. The company expects high single-digit EPS growth in fiscal '26, excluding tariff impacts.
Q:What are the implications of the new operating model changes and commercial team alignment for New BD?
A:Thomas Polen described the creation of a Chief Revenue Officer role and the reallocation of $50 million in corporate costs to businesses. Investments are being made in high-growth, high-margin markets and innovation. The changes aim to drive commercial excellence and long-term profitable growth, with benefits expected to start materializing in fiscal '26.
Q:What is the long-term outlook for operating margin expansion?
A:Thomas Polen stated that BD Excellence and innovation will continue to drive gross margin expansion. Investments in higher-growth, higher-margin spaces and operational improvements are expected to support ongoing operating margin growth beyond the current 25% level.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact long-term operating margin target, stating only that there is room for further expansion. Additionally, the response on China dynamics lacked clarity on how VoBP will evolve and its precise impact on future performance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APM
Alaris pump
Biologics digit
CFO
Connected Care
DS
Diagnostic Solutions
EMEA demand
FACSDiscover platform
MMS record
New BD
Pharm Systems
President Investor
Systems Biologics
cost
demand FACSDiscover
demand vaccine
digit BD
digit forma
hand
model
moment
organic New
point basis
point tariff
profile
pump installation
sale EMEA
sale force
tissue regeneration
transition
unit
work
BDX Transcript
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture. While there are positive elements like growth in medical essentials and connected care, strong cash flow, and confidence in future revenue and margin performance, there are concerns. The decline in biopharma systems, adjusted gross margin decrease, and lack of clarity on certain future projections temper optimism. The strategic focus on share repurchases and productivity improvements is positive, but headwinds from Alaris and China, and the temporary ship hold on ChloraPrep, introduce uncertainties. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Casey's General Stores, Inc. (CASY) Q3 2026 Earnings Call Transcript
Positive3-10
The strategic plan outlines positive initiatives such as share buybacks, innovation investments, and cost optimization, which are likely to bolster market sentiment. Despite challenges like tariff headwinds and revenue declines in specific segments, the company maintains stable margins and optimistic EPS growth. The Q&A insights reveal effective management of external factors and growth strategies, further supporting a positive outlook. These elements collectively suggest a positive stock price movement over the next two weeks.
Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
BDX Slides
BDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
